Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), afatinib, has been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired resistance to afatinib has not been well studied. In this study, we established afatinib ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinwen, Zhang, Fupeng, Yang, Xi, Xue, Meiping, Li, Xiaoli, Gao, Yu, Liu, Likun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848392/
https://www.ncbi.nlm.nih.gov/pubmed/30832751
http://dx.doi.org/10.3727/096504018X15426271404407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848392/
https://www.ncbi.nlm.nih.gov/pubmed/30832751
http://dx.doi.org/10.3727/096504018X15426271404407

Ejemplares similares